Study of resistant GIST using PET scans and genetics
Part of Cancer, Digestive system clinical trials.
This trial studies advanced GIST cancers that have stopped responding to all four standard treatments. It uses PET-CT scans and genetic testing of tumor tissue to understand resistance, helping to find the best next treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced GIST (gastrointestinal stromal tumor) and have already tried and failed (or cannot take) all four standard drugs: imatinib, sunitinib, regorafenib, and ripretinib.
- Your tumor must have a mutation in the KIT or PDGFRA gene.
- You are 18 or older, not pregnant or breastfeeding, and physically able to undergo imaging (PET-CT) and possibly a tumor biopsy.
- Previous CT, MRI, or PET scans of your abdomen are available to compare your tumor’s growth over time.
- A growing tumor is accessible for a biopsy (optional but encouraged).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This study uses a special type of MRI to see how well imatinib, a targeted cancer pill, is working in people with GIST. It may help doctors understand which patients are responding best to treatment.
This study looks at how surgery for gastrointestinal stromal tumors (GIST) works, and collects tumor samples to study them under the microscope and by DNA testing. Your results may help researchers better predict tumor behavior and guide future treatment.
This study follows people who have been taking targeted cancer drugs (called TKIs) for advanced GIST for at least 2 years to understand how these long-term treatments affect quality of life, side effects, and daily living. Researchers want to learn what challenges patients face and how to better support them.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This study tests a combination of two drugs—regorafenib (a targeted therapy) and envafolimab (an immunotherapy)—for people with advanced GIST whose tumors have a specific KIT gene mutation (exon 17) and have stopped responding to standard treatments.
Hear when a new Gastrointestinal Stromal Tumor (GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.